Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575699 · ClinicalTrials.gov registry record · Phase 4
Rectus Sheath Block for Analgesia After Gynecological Laparotomy
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT06575699: Completed Phase 4 study, sponsored by Duke University.
NCT06575699 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06575699, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block (RSB) under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:2 ratio by age, race, insurance status and duration of surgery with historical controls who received postoperative analgesia using thoracic epidural analgesia.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivacaine Hydrochloride
- PROCEDURE Rectus sheath block
- PROCEDURE Thoracic Epidural Analgesia
- DRUG Bupivacaine-Hydromorphone Cassette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2025-11-28 |
| Phase | Phase 4 |
What the finished NCT06575699 record still lists
NCT06575699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which Liposomal bupivacaine is the first listed.
NCT06575699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06575699 about?
NCT06575699 is a clinical study titled "Rectus Sheath Block for Analgesia After Gynecological Laparotomy". Thirty subjects undergoing laparotomy for Gynecologic oncology surgery will be prospectively enrolled and will receive a bilateral rectus sheath block (RSB) under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side. Cases will be matched in a 1:2 ratio by age,...
What is the current status of trial NCT06575699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2024-10-10. Estimated completion is 2025-11-28.
What interventions are being tested in trial NCT06575699?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG), Rectus sheath block (PROCEDURE), Thoracic Epidural Analgesia (PROCEDURE), Bupivacaine-Hydromorphone Cassette (DRUG).
Who is sponsoring clinical trial NCT06575699?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06575699's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI